Delcath Systems Launches Phase II Trial of Hepzato for Liver-Dominant Colorectal Cancer

Delcath Systems Launches Phase II Trial of Hepzato for Liver-Dominant Colorectal Cancer

Delcath Systems has commenced a Phase II clinical trial evaluating the efficacy of Hepzato (melphalan/Hepatic Delivery System) in combination with trifluridine-tipiracil and bevacizumab for treating liver-dominant metastatic colorectal cancer (mCRC). The study, which began at the City of Hope National Medical Center, will enroll around 90 patients across the U.S. and Europe. The primary endpoint is hepatic progression-free survival, with results…